[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR112016008276B1 - derivados bicíclicos de piridila fundidos ao anel, seus usos e seu intermediário, e composição farmacêutica - Google Patents

derivados bicíclicos de piridila fundidos ao anel, seus usos e seu intermediário, e composição farmacêutica Download PDF

Info

Publication number
BR112016008276B1
BR112016008276B1 BR112016008276-1A BR112016008276A BR112016008276B1 BR 112016008276 B1 BR112016008276 B1 BR 112016008276B1 BR 112016008276 A BR112016008276 A BR 112016008276A BR 112016008276 B1 BR112016008276 B1 BR 112016008276B1
Authority
BR
Brazil
Prior art keywords
naphthyridine
carboxamide
dihydro
formyl
cyano
Prior art date
Application number
BR112016008276-1A
Other languages
English (en)
Portuguese (pt)
Inventor
Nicole Buschmann
Robin Alec Fairhurst
Pascal Furet
Thomas Knopfel
Catherine Leblanc
Robert Mah
Pierre Nimsgern
Sebastien Ripoche
Lv LIAO
Jing Xiong
Xianglin ZHAO
Bo Han
Can Wang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112016008276B1 publication Critical patent/BR112016008276B1/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53831,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541Non-condensed thiazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
BR112016008276-1A 2013-10-25 2014-10-24 derivados bicíclicos de piridila fundidos ao anel, seus usos e seu intermediário, e composição farmacêutica BR112016008276B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2013086003 2013-10-25
CNPCT/CN2013/086003 2013-10-25
CN2014088094 2014-10-03
CNPCT/CN2014/088094 2014-10-03
PCT/IB2014/065585 WO2015059668A1 (en) 2013-10-25 2014-10-24 Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors

Publications (1)

Publication Number Publication Date
BR112016008276B1 true BR112016008276B1 (pt) 2021-03-02

Family

ID=52003015

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016008276-1A BR112016008276B1 (pt) 2013-10-25 2014-10-24 derivados bicíclicos de piridila fundidos ao anel, seus usos e seu intermediário, e composição farmacêutica

Country Status (27)

Country Link
US (3) US9266883B2 (pl)
EP (1) EP3060563B1 (pl)
JP (3) JP6203954B2 (pl)
KR (1) KR101862493B1 (pl)
CN (1) CN105683188B (pl)
AP (1) AP2016009156A0 (pl)
AU (1) AU2014338549B2 (pl)
BR (1) BR112016008276B1 (pl)
CA (1) CA2927252C (pl)
CL (1) CL2016000922A1 (pl)
CR (1) CR20160191A (pl)
DO (1) DOP2016000094A (pl)
EA (1) EA028819B1 (pl)
ES (1) ES2682493T3 (pl)
HK (1) HK1222388A1 (pl)
IL (2) IL244819B (pl)
MX (2) MX367723B (pl)
NI (1) NI201600058A (pl)
PE (1) PE20160546A1 (pl)
PH (1) PH12016500756A1 (pl)
PL (1) PL3060563T3 (pl)
PT (1) PT3060563T (pl)
SG (1) SG11201602183QA (pl)
SV (1) SV2016005186A (pl)
TN (1) TN2016000115A1 (pl)
TR (1) TR201810944T4 (pl)
WO (1) WO2015059668A1 (pl)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY152955A (en) 2007-12-10 2014-12-15 Novartis Ag Pyrazine-2-carboxamide derivatives to treat diseases mediated by blockade of the epithelial sodium channel
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
WO2013171640A1 (en) * 2012-05-15 2013-11-21 Novartis Ag Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
SI3495367T1 (sl) 2012-06-13 2021-01-29 Incyte Holdings Corporation Substituirane triciklične spojine kot zaviralci FGFR
NZ703495A (en) * 2012-07-11 2018-02-23 Blueprint Medicines Corp Inhibitors of the fibroblast growth factor receptor
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
JP6449244B2 (ja) 2013-04-19 2019-01-09 インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation Fgfr抑制剤としての二環式複素環
EP3395814B1 (en) 2013-10-25 2022-04-06 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
US9695165B2 (en) 2014-01-15 2017-07-04 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor
JP6585167B2 (ja) * 2014-10-03 2019-10-02 ノバルティス アーゲー Fgfr4阻害剤としての縮環二環式ピリジル誘導体の使用
EA032839B1 (ru) 2014-10-03 2019-07-31 Юсб Байофарма Спрл Конденсированные пентациклические производные имидазола
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
AU2016219822B2 (en) 2015-02-20 2020-07-09 Incyte Holdings Corporation Bicyclic heterocycles as FGFR inhibitors
US9802917B2 (en) 2015-03-25 2017-10-31 Novartis Ag Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide
WO2016151501A1 (en) * 2015-03-25 2016-09-29 Novartis Ag Pharmaceutical combinations
KR20170114254A (ko) * 2016-03-24 2017-10-13 재단법인 대구경북첨단의료산업진흥재단 신규한 피리딘 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 fgfr 관련 질환의 예방 또는 치료용 약학적 조성물
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Hdac抑制劑與pd-l1抑制劑之組合治療
WO2017198221A1 (zh) 2016-05-20 2017-11-23 浙江海正药业股份有限公司 嘧啶类衍生物、其制备方法和其在医药上的用途
JP7103952B2 (ja) * 2016-05-20 2022-07-20 江▲蘇▼豪森▲薬▼▲業▼集▲団▼有限公司 Fgfr4阻害剤、その製造方法及び応用
WO2017202390A1 (zh) * 2016-05-27 2017-11-30 杭州英创医药科技有限公司 作为fgfr4抑制剂的杂环化合物
CN107619388A (zh) 2016-07-13 2018-01-23 南京天印健华医药科技有限公司 作为fgfr抑制剂的杂环化合物
US11608332B2 (en) * 2016-08-12 2023-03-21 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. FGFR4 inhibitor and preparation method and use thereof
WO2018049233A1 (en) * 2016-09-08 2018-03-15 Nicolas Stransky Inhibitors of the fibroblast growth factor receptor in combination with cyclin-dependent kinase inhibitors
CN107840842A (zh) 2016-09-19 2018-03-27 北京天诚医药科技有限公司 炔代杂环化合物、其制备方法及其在医药学上的应用
WO2018055503A1 (en) 2016-09-20 2018-03-29 Novartis Ag Combination comprising a pd-1 antagonist and an fgfr4 inhibitor
MA46712A (fr) 2016-11-02 2019-09-11 Novartis Ag Combinaisons d'inhibiteurs de fgfr4 et de chélateurs de l'acide biliaire
CN108264510A (zh) * 2017-01-02 2018-07-10 上海喆邺生物科技有限公司 一种选择性抑制激酶化合物及其用途
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
JP7346420B2 (ja) 2017-09-05 2023-09-19 バイオアーディス エルエルシー 芳香族誘導体、その調製方法、およびその医学的適用
CN111164075A (zh) * 2017-09-20 2020-05-15 北京加科思新药研发有限公司 用作fgfr4抑制剂的稠环衍生物
CN110225913B (zh) * 2017-10-31 2021-10-15 江苏豪森药业集团有限公司 Fgfr4抑制剂晶型及其制备方法
WO2019085927A1 (zh) * 2017-10-31 2019-05-09 江苏豪森药业集团有限公司 Fgfr4抑制剂的盐、晶体、制备方法及其用途
CN109745321B (zh) * 2017-11-08 2022-04-29 上海翰森生物医药科技有限公司 包含fgfr4抑制剂的药物组合物
CN109928968B (zh) * 2017-12-15 2021-11-05 成都华健未来科技有限公司 一类制备抗癌药物的中间体
US11466004B2 (en) 2018-05-04 2022-10-11 Incyte Corporation Solid forms of an FGFR inhibitor and processes for preparing the same
EA202092649A1 (ru) 2018-05-04 2021-06-21 Инсайт Корпорейшн Соли ингибитора fgfr
CN111285871A (zh) * 2018-07-05 2020-06-16 成都华健未来科技有限公司 一种脲类化合物的新型晶型产品及制备方法
CN111285869A (zh) * 2018-07-05 2020-06-16 成都华健未来科技有限公司 脲类化合物的新型晶型产品及制备方法
TWI723480B (zh) * 2018-07-27 2021-04-01 大陸商北京加科思新藥研發有限公司 用作fgfr4抑制劑的稠環衍生物
WO2020177067A1 (en) 2019-03-05 2020-09-10 Bioardis Llc Aromatic derivatives, preparation methods, and medical uses thereof
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
KR20210142154A (ko) 2019-03-21 2021-11-24 옹쎄오 암 치료를 위한 키나제 억제제와 조합된 dbait 분자
WO2020236779A1 (en) * 2019-05-21 2020-11-26 Westrock Packaging Systems, Llc Flexible pitch product metering system
JP2022537415A (ja) * 2019-06-21 2022-08-25 ターンズ・ファーマシューティカルズ・インコーポレイテッド Fgfr4を阻害するための化合物
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
AU2020366006A1 (en) 2019-10-14 2022-04-21 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
CN115151539A (zh) 2019-12-04 2022-10-04 因赛特公司 Fgfr抑制剂的衍生物
JP2023505258A (ja) 2019-12-04 2023-02-08 インサイト・コーポレイション Fgfr阻害剤としての三環式複素環
CN113072550B (zh) * 2020-01-06 2023-08-08 周龙兴 一种高选择性成纤维细胞生长因子受体抑制剂和应用
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
JPWO2022075482A1 (pl) 2020-10-05 2022-04-14
CN116528866A (zh) * 2020-11-02 2023-08-01 北京加科思新药研发有限公司 Fgfr4抑制剂的盐的晶型
CA3215903A1 (en) 2021-04-12 2022-10-20 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
AR126102A1 (es) 2021-06-09 2023-09-13 Incyte Corp Heterociclos tricíclicos como inhibidores de fgfr
CN115504965A (zh) 2021-06-23 2022-12-23 浙江海正药业股份有限公司 嘧啶类衍生物的晶型及其制备方法
CN116102549A (zh) * 2021-11-09 2023-05-12 暨南大学 5-醛基杂环酰胺类化合物及其应用
WO2023082044A1 (zh) * 2021-11-09 2023-05-19 暨南大学 5-醛基杂环酰胺类化合物及其应用

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9420999D0 (en) 1994-10-18 1994-12-07 Smithkline Beecham Plc Novel compounds
US6140338A (en) 1996-07-29 2000-10-31 Banyu Pharmaceutical, Co., Ltd. Chemokine receptor antagonists
BR9813769A (pt) 1997-12-17 2000-10-10 Merck & Co Inc Composto, composição farmacêutica, e, processos para fabricar a mesma, para evocar um efeito antagonizante do receptor da integrina em um mamìfero em necessidade deste, para tratar ou prevenir uma condição mediada pelo antagonismo de um receptor da integrina em um mamìfero em necessidade deste, para inibir a reabsorção óssea em um mamìfero em necessidade deste, e para tratar o desenvolvimento tumoral em um mamìfero em necessidade deste.
AU2832399A (en) 1998-02-10 1999-08-30 Novartis Ag B cell inhibitors
US7115750B1 (en) 1999-09-20 2006-10-03 Takeda Pharmaceutical Company Limited Melanin concentrating hormone antagonist
CN1414966A (zh) * 1999-11-08 2003-04-30 麦克公司 用于制备咪唑烷酮αu蛋白拮抗剂的方法和中间体
EP1475368A4 (en) 2002-02-14 2006-03-29 Ono Pharmaceutical Co FUSED CORE COMPOUNDS CONTAINING N-CARBAMOYL NITROGEN AND MEDICAMENTS CONTAINING SAID COMPOUNDS AS ACTIVE INGREDIENTS
EP1541563A4 (en) 2002-07-10 2007-11-07 Ono Pharmaceutical Co ANTAGONIST OF CCR4 AND CORRESPONDING MEDICINAL USE
CA2510851A1 (en) 2002-12-20 2004-07-08 Warner-Lambert Company Llc Benzoxazines and derivatives thereof as inhibitors of pi3ks
US7098332B2 (en) * 2002-12-20 2006-08-29 Hoffmann-La Roche Inc. 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
JP4736043B2 (ja) 2003-03-14 2011-07-27 小野薬品工業株式会社 含窒素複素環誘導体およびそれらを有効成分とする薬剤
EP1613322A4 (en) 2003-04-11 2008-08-13 Taigen Biotechnology Co Ltd AMINOQUINOLINE COMPOUNDS
CA2538820A1 (en) 2003-09-11 2005-03-17 Kemia, Inc. Cytokine inhibitors
WO2007009883A1 (en) 2005-07-15 2007-01-25 F. Hoffmann-La Roche Ag Novel heteroaryl fused cyclic amines
SMP200800041B (it) * 2005-12-21 2009-07-14 Novartis Ag Derivati di pirimidinil-aril-urea attivi come-fgf-inibitori
CN101405002A (zh) 2005-12-29 2009-04-08 詹森药业有限公司 激肽原2受体拮抗剂
CA2637988A1 (en) 2006-02-10 2007-11-29 Genentech, Inc. Anti-fgf19 antibodies and methods using same
JPWO2007105637A1 (ja) 2006-03-10 2009-07-30 小野薬品工業株式会社 含窒素複素環誘導体およびそれらを有効成分とする薬剤
WO2007146230A2 (en) 2006-06-14 2007-12-21 Merck & Co., Inc. Non-nucleoside reverse transcriptase inhibitors
EP1918376A1 (en) 2006-11-03 2008-05-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. FGFR4 promotes cancer cell resistance in response to chemotherapeutic drugs
JP2010520881A (ja) 2007-03-09 2010-06-17 ノバルティス アーゲー 黒色腫の処置
CA2682096A1 (en) 2007-04-02 2009-01-15 Genentech, Inc. Klotho beta
US20110150833A1 (en) 2007-12-21 2011-06-23 The Scripps Research Institute Benzopyrans and analogs as rho kinase inhibitors
FR2933702A1 (fr) 2008-07-08 2010-01-15 Sanofi Aventis Antagonistes specifiques du recepteur fgf-r4
CN102224170A (zh) 2008-09-03 2011-10-19 利琴蒂亚有限公司 抑制与fgfr4相关的癌细胞侵袭的材料和方法
WO2010027002A1 (ja) 2008-09-05 2010-03-11 塩野義製薬株式会社 Pi3k阻害活性を有する縮環モルホリン誘導体
CR20110389A (es) 2008-12-19 2011-07-13 Abbott Lab Compuestos y métodos de uso
GB0906472D0 (en) * 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
WO2010129467A1 (en) 2009-05-04 2010-11-11 Plexxikon, Inc. Compounds and methods for inhibition of renin, and indications therefor
BR112012010010A2 (pt) 2009-10-29 2018-03-20 Sirtris Pharmaceuticals Inc piridinas bicíclicas e análogos como moduladores da sirtuína
US20120220600A1 (en) 2009-10-30 2012-08-30 Reiner Aichholz N-Oxide of 3-(2,6-dichloro-3,5-dimethoxy-phenyl) -1--1-methyl-urea
WO2011093501A1 (ja) 2010-02-01 2011-08-04 日本ケミファ株式会社 Gpr119作動薬
WO2011111880A1 (ko) 2010-03-08 2011-09-15 주식회사 메디젠텍 세포핵에서 세포질로의 gsk3의 이동을 억제하는 화합물을 함유하는 세포핵에서 세포질로의 gsk3 이동에 의해 발생되는 질환의 치료 또는 예방용 약학적 조성물
WO2012016217A1 (en) 2010-07-29 2012-02-02 Rigel Pharmaceuticals, Inc. Ampk-activating heterocyclic compounds and methods for using the same
JP5620417B2 (ja) * 2011-02-07 2014-11-05 中外製薬株式会社 アミノピラゾール誘導体を含む医薬
WO2012127388A1 (en) 2011-03-18 2012-09-27 Lupin Limited Benzo [b] [1, 4] oxazin derivatives as calcium sensing receptor modulators
EP2694551A1 (en) 2011-04-07 2014-02-12 Genentech, Inc. Anti-fgfr4 antibodies and methods of use
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
NZ703495A (en) 2012-07-11 2018-02-23 Blueprint Medicines Corp Inhibitors of the fibroblast growth factor receptor
US9315519B2 (en) 2012-10-12 2016-04-19 Bristol-Myers Squibb Company Guanidine substituted tetrahydroisoquinoline compounds as factor XIa inhibitors
WO2014059214A1 (en) 2012-10-12 2014-04-17 Bristol-Myers Squibb Company Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
WO2014079709A1 (en) 2012-11-23 2014-05-30 Ab Science Use of small molecule inhibitors/activators in combination with (deoxy)nucleoside or (deoxy)nucleotide analogs for treatment of cancer and hematological malignancies or viral infections
US9663524B2 (en) 2013-03-15 2017-05-30 Celgene Car Llc Substituted pyrido[2,3-d]pyrimidines as protein kinase inhibitors
JP6449244B2 (ja) 2013-04-19 2019-01-09 インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation Fgfr抑制剤としての二環式複素環
GB201307577D0 (en) 2013-04-26 2013-06-12 Astex Therapeutics Ltd New compounds
EP3019491A4 (en) 2013-07-09 2016-12-21 Dana Farber Cancer Inst Inc KINASE INHIBITORS FOR THE TREATMENT OF DISEASE
AR097455A1 (es) 2013-08-28 2016-03-16 Astellas Pharma Inc Composición farmacéutica que contiene compuesto de pirimidina como un ingrediente activo
HUE039268T2 (hu) 2013-10-18 2018-12-28 Eisai R&D Man Co Ltd Pirimidin FGFR4 inhibitorok
EP3395814B1 (en) 2013-10-25 2022-04-06 Blueprint Medicines Corporation Inhibitors of the fibroblast growth factor receptor

Also Published As

Publication number Publication date
MX2019010446A (es) 2019-10-17
EA028819B1 (ru) 2018-01-31
SV2016005186A (es) 2016-11-21
EA201690848A1 (ru) 2016-08-31
KR101862493B1 (ko) 2018-05-29
IL263404A (en) 2018-12-31
NI201600058A (es) 2016-06-21
WO2015059668A1 (en) 2015-04-30
MX2016005394A (es) 2016-08-12
HK1222388A1 (zh) 2017-06-30
JP2017214411A (ja) 2017-12-07
TN2016000115A1 (en) 2017-07-05
ES2682493T3 (es) 2018-09-20
MX367723B (es) 2019-09-03
US20160102092A1 (en) 2016-04-14
IL244819B (en) 2018-12-31
CA2927252C (en) 2021-09-28
AP2016009156A0 (en) 2016-04-30
US9266883B2 (en) 2016-02-23
JP2016534072A (ja) 2016-11-04
EP3060563B1 (en) 2018-05-02
PH12016500756A1 (en) 2016-05-30
IL244819A0 (en) 2016-05-31
KR20160075644A (ko) 2016-06-29
CA2927252A1 (en) 2015-04-30
DOP2016000094A (es) 2016-07-15
SG11201602183QA (en) 2016-05-30
CR20160191A (es) 2016-07-01
US20150119385A1 (en) 2015-04-30
AU2014338549A1 (en) 2016-04-14
JP6429954B2 (ja) 2018-11-28
AU2014338549B2 (en) 2017-05-25
IL263404B (en) 2019-09-26
TR201810944T4 (tr) 2018-08-27
EP3060563A1 (en) 2016-08-31
JP6745856B2 (ja) 2020-08-26
AU2014338549A8 (en) 2016-04-21
US20170066766A1 (en) 2017-03-09
JP6203954B2 (ja) 2017-09-27
CN105683188A (zh) 2016-06-15
CL2016000922A1 (es) 2017-01-27
PL3060563T3 (pl) 2018-10-31
PE20160546A1 (es) 2016-05-26
JP2019031553A (ja) 2019-02-28
PT3060563T (pt) 2018-07-26
US9533988B2 (en) 2017-01-03
CN105683188B (zh) 2018-02-09
US9896449B2 (en) 2018-02-20

Similar Documents

Publication Publication Date Title
JP6745856B2 (ja) Fgfr4阻害剤としての縮環二環式ピリジル誘導体
KR101961500B1 (ko) 세린/트레오닌 키나제 억제제
EP3121177B1 (en) Combinations of trpv4 antagonists
JP2019081786A (ja) Trkaキナーゼ阻害剤としてのn−ピロリジニル、n’−ピラゾリル尿素、チオ尿素、グアニジン、およびシアノグアニジン化合物
IL256250A (en) Hpk1 inhibitors and methods of using them
BR112016011024B1 (pt) Composto, composição farmacêutica, e, usos dos mesmos
CA3107365A1 (en) Pyrazine compounds and uses thereof
MX2007000116A (es) Pirimidinas 2,4,6-trisustituidas como inhibidores de fosfotidilinositol (pi) 3-cinasa y su uso en el tratamiento de cancer.
AU2022214618A1 (en) Cdk2 inhibitors and methods of using the same
JP7384535B2 (ja) キナゾリン化合物並びにその調製方法、使用及び医薬組成物
JP2024519215A (ja) Cdk2分解剤およびそれらの使用
JP2016514709A (ja) ヤヌスキナーゼ阻害剤としてのジェミナル置換シアノエチルピラゾロピリドン
CA3117512A1 (en) 5-azaindazole derivatives as adenosine receptor antagonists
TWI690528B (zh) 稠環雙環吡啶基衍生物

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/10/2014, OBSERVADAS AS CONDICOES LEGAIS.